

Banisteriopsis Species: A Source of Bioactive of Potential Medical Application

Ulysses A. de Frias^{1,*}, Maria Cristina Mendes Costa¹, Jacqueline Aparecida Takahashi² and Yumi Oki³

¹Núcleo de Pesquisa Ciências Biológicas, Centro Universitário de Lavras, Rua Padre José Poggel, 506, CEP 37200-000, Lavras, MG, Brazil

²Laboratório de Biotecnologia e Bioensaios, Departamento de Química, ICEx, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6624, CEP 31270-901, Belo Horizonte, MG, Brazil

³Laboratório de Ecologia Evolutiva e Biodiversidade, ICB, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6624, CEP 31270-901, Belo Horizonte, MG, Brazil

Abstract: In recent years, interest in further development of herbal or botanical drug products derived from traditional preparations has been increasing steadily. Plants have been used for thousands of years to treat health disorders and to prevent diseases including epidemics. Several research works have been developed to search for new natural products to be used in pharmaceutical products. Active compounds produced during secondary metabolism are responsible for the biological properties of the plant species and may be used to most diverse purposes, including treatment of several diseases. *Banisteriopsis* species has been described showing interesting activities by its use in popular medicine. The mainly use was described to production of the Ayahuasca, an Amazonian psychotropic plant tea obtained from *Banisteriopsis caapi*, which contains β -carboline alkaloids, mainly harmine, harmaline and tetrahydroharmine. Other species of *Banisteriopsis* genus have been described with biological metabolites as antimicrobial, anticholinesterase, anti-anxiety and others. These biological activities were described chiefly by the presence of alkaloids, flavonoids, tannins. Thus, to stimulate the study into the *Banisteriopsis* genus, the purpose of the present review is to gather information on the use of the extracts and metabolites of *Banisteriopsis* species (Malpighiaceae) as a resource to diseases treatment or to pharmaceutical purposes.

Keywords: *Banisteriopsis*, alkaloids, harmine, harmaline, flavonoids, quercetin, tannins, terpenoids, *Ayahuasca*, bioactivities.

INTRODUCTION

Banisteriopsis is one of the largest and most widespread genera of the Malpighiaceae family, this neotropical genus is represented by ca 92 species and distributed mainly in Brazil, Bolivia, Colombia, Ecuador, and Peru [1, 2].

The isolated use of plants of the genus *Banisteriopsis*, or its association with *Psychotria viridis* or *Diplopterys cabrerana* give rise to *Ayahuasca* tea [3, 4], term which literally translates as "vine of the soul". The hallucinogenic tea, also known as "Santo Daime's" tea, "hoasca", "Daime", "yajé" or "Natema", is traditionally used in religions celebrations by indigenous peoples of the Amazonian and Andean forests [5-8].

This tea is prepared by aboriginal and indigenous Mestizo populations of Amazon rainforest and Andes using two different plants: the stems from

Banisteriopsis caapi and the leaves from *Psychotria viridis* [4, 9].

These effects can be primarily associated to harmine (1), harmaline (2) and tetrahydroharmine (3) found in *B. caapi* that act reversibly inhibiting monoamine oxidase A (MAO-A). Their combination with the indole alkaloid N,N-Dimethyltryptamine (DMT) (4) found in leaves of *P. viridis*, which is structurally similar to the monoamine neurotransmitter serotonin (5) acts on receptors 5-HT_{2A/2C} like a potent psychedelic agent giving to the user the hallucinogenous sensation [3]. Recently also been shown that harmine binds to imidazoline receptors and dopamine transporters [10].

Usually, DMT is a potent and short acting psychedelic agent, but it is rapid oxidation by MAO-A. In the *Ayahuasca*, MAO-A is inhibited by the harmine, thus the DMT causes an agonistic effect on serotonergic receptors [9]. In Brazil, there are other species that also contains this tryptamine in their leaves, such as *Psychotria cartagenensis* and *Diplopterys cabrerana* syn. *Banisteriopsis rusbyana* [11].

*Address corresponding to this author at the Núcleo de Pesquisa em Ciências Biológicas, Centro Universitário de Lavras, Rua Padre José Poggel, 506, CEP 37200-000, Brazil; Tel: +55-16-8225-9326; E-mail: ulyssesmanzo@gmail.com

Numerous bioactive metabolites have been found in *Banisteriopsis* species. Among biological properties described for the studied species are: antinociceptive and analgesic effects [12, 13], anticancer properties [14-16], antiproliferative [17], vasorelaxant [18-20] and hypothermic properties [21, 22], antimicrobial activity [23, 24], strong reversible inhibition of monoamine oxidase [25, 26] and inhibitory activity against acetylcholinesterase [27].

Bussmann *et al.* (2010) showed that ethanolic and aqueous extracts of *Banisteriopsis caapi* have interesting activity on *Escherichia coli* demonstrating to be interesting candidates for future research [28]. In the popular medicine, *Banisteriopsis* species have been used to treatment of topic fugal disease. Freitas (2010) proved the utilization of leaves aqueous extract of *B. anisandra* against *Candida albicans*, *C. krusei*, *C. parapsilosis* and *C. tropicalis* inhibited these yeasts in the same way than fluconazole, a triazole antifungal drug [29]. Hexane, ethyl acetate and methanol extract did not show inhibitory activity against *C. albicans* [30].

ALKALOIDS

Some species of *Banisteriopsis*, as *B. caapi*, can be highlighted by its high level of pharmacologically active alkaloids produced, mainly of β -carboline (β -CA) as harmine (HMR), harmaline (HML), tetrahydroharmine (THH) [9]. Other β -CA's also found are harmalinic acid (**6**), harmic amide, harmine-N-oxide (**7**), harmic acid methylester (**8**), norharmine (**9**), ketotetrahydronorharmine (**10**) [31,32] and the alkaloids pyrrolidine bases shihunine (**11**) and S-(+) dihydroshihunine (**12**) [33]. In aqueous extracts, Samoylenko *et al.* (2010) reported the isolation of two alkaloidal glycosides, named banistenoside A (**13**) and banistenoside B (**14**), structure based from the azepino[1,2-a]tetrahydro- β -carboline and the know β -CA harmol (**15**) [34]. From leaves of *B. argetea* it was found the presence of the alkaloids (+)-N-methyl-tetrahydroharmine (**16**), 5-methoxy-tetrahydroharmine (5-MeO-THH) (**17**), N,N-dimethyltryptamine-N-oxide (**18**), N,N-dimethyltryptamine, TTH, harmaline, betaine (**19**) and coline (**20**) [35].




Figure 1: Example of nitrogenous compounds found in *Banisteriopsis* species and similar substances.

The β -CA's present a wide spectrum of therapeutic activities such as: antianxiety, mood control, panic-like, hopelessness and antidepressant effects. The exogenous administration of β -CA's have demonstrated a reduction in the behaviors associated with depression and anxiety in rats [8]. These effects appear to be linked with the increase of extra cellular dopamine and serotonin caused by the inhibition of MAO-A and by the increase of their respective metabolites, homovanillic acid, and 5-hydroxyindole acetic acid levels. The β -CA's are a potent endogenous ligand of the benzodiazepine receptor, causing the stimulation of this receptor in an inverse way [8, 36].

Individually, the β -CA's found in *Banisteriopsis* species showed antimicrobial effects against many species of microorganisms. In *B. caapi* extract, harmine showed effects against *Proteus vulgaris*, *Bacillus subtilis* and *Candida albicans*, while harmaline was effective against *P. vulgaris* and *C. albicans* [37].

Im *et al.* (2009) evaluated the effect of β -CA's on collagen-induced PLC γ 2 activation in washed rabbit platelets in which harmine and harmaline displayed a complete suppression on collagen-induced PLC γ 2 phosphorylation demonstrating that β -carboline alkaloids have structural antiplatelet activity [38]. It was reported the potential to reduce systemic arterial blood pressure by the administration of harmine and the vasorelaxant activity of harmaline with a hypotensive effect. Thus the beneficial property of harmine and harmaline on cardiovascular system may be relevant in the inhibition of thrombus formation by an anti-aggregation platelet activity [39].

Ayahuasca was reported like a prophylactic agent against malaria and other parasites [40]. Hopp *et al.* (1976) observed that harmine exhibited significant anti-trypanosomal activity against *Trypanosoma lewisii* [41]. Harmine and harmaline have been also reported like an inhibitory activity against *Plasmodium* species (Malaria disease) [42, 43]. Astulla *et al.* (2008) evaluated the inhibitory effects and showed a moderate *in vitro* antiplasmodial activity against *P. falciparum* (harmine: IC₅₀ 8.0 μ g/ml; harmaline IC₅₀: 25.1 μ g/ml) [20].

Moreover β -CA's showed the inhibitor potential of multiple cytochrome P450 enzymes, could be influence the hepatic activities. Harmine and harmaline inhibited the activity of CYP3A4 mediated by testosterone 6 β hydroxylation suggested by the authors as the result of a noncompetitive inhibition. However

harmaline, harmine and harmaline exhibited a moderate inhibition on CYP2D6 suggesting a competitive inhibition [44].

El Gendy (2012) observed that harmine and its metabolite, harmaline, are new inhibitors of dioxin-mediated effects. Harmine and harmaline significantly inhibited the dioxin-mediated induction of CYP1A1 at mRNA, protein, and activity levels in a concentration-dependent manner in human and murine hepatoma cells. At post-translational level, harmine and harmaline decreased the protein stability of CYP1A1, suggesting that posttranslational mechanism is involved [45, 46].

Mono amino oxidase inhibitors MAOIs are used for the treatment of depressive disorders, anxiety disorders, Parkinson's disease, and Alzheimer's disease. This BCA's may attenuate the dopamine- and 6-hydroxydopamine (6-OHDA)-induced anterad brain mitochondrial and synaptic functions and viability loss in PC12 cells. The study demonstrated the property to decrease alterations of the Ca²⁺, and succinate-induced swelling and membrane potential formation in mitochondria caused by preincubation of catecholamines. BCA's showed protective effects on dopamine-induced mitochondrial damage provided a defense against 6-hydroxydopamine (6-OHDA). This property can help in the treatment of the Parkinson's disease (PD) because dopamine is preferentially deaminated by MAO-B in the human brain, MAO-B inhibitors should increase the basal central dopamine levels in patients with PD, one time the BCA's in elevated concentrations may exert a protective effect on oxidative neuronal damage attenuating of mitochondrial and synaptic dysfunction [47].

MAO-B inhibition also has neuroprotective effects. Remarkably, MAO-B activity increases in aging and is particularly high around senile plaques in patients with Alzheimer's disease. By inhibiting MAO-B, the neurodegenerative processes that occur in the Alzheimer's disease brain would be suppressed [48] or by the inhibition of the acetylcholinesterase [30].

Miralles (2005) determined the affinity and binding profile of harmine and harmaline for imidazoline I₂ receptors and catalytic sites of monoamine oxidase (MAO)-A/B in rat brain and liver and showed that BCA's bind with high affinity to imidazoline I_{2B} receptors, and similarly to I₂ ligands (LSL 60101) can block the behavioral and biochemical effects of opiate withdrawal. These results suggest that some BCA's and selective imidazoline I₂ drugs can be useful agents




Figure 2: Flavonoids founded in *Banisteriopsis* species.

for the treatment of the opiate abstinence syndrome in humans [49]. The BCA's also stimulate locus coeruleus neurons in anaesthetized rats, showing this stimulation occurs directly in the LC by a mechanism independent of I_1 - and I_2 - imidazoline receptors [50].

FLAVONOIDS

Flavonoids are a group of polyphenols widely occurring in plants and foods of plant origin. Inside this pharmacognostic class, many exhibit a multitude of biological activities like anticarcinogenic [51, 52], antioxidative [53], enzyme-modulating activities [54-56] and protective effect on cardiovascular disease [57, 58].

In preliminary studies, Frias *et al.* (2011) founded flavonoids associated to the flowers and leaves of the *B. anisandra*, *B. campestri*, *B. laevifolia* and *B. malifolia* [59]. *B. variabilis* extract showed activity against bovine herpes viruses type 1 (BoHV-1), and S133 strain withdraw avian reovirus [60]. From metanolic extract of *B. variabilis*, there were isolated the flavonoids quercetin (**21**), rutin (**22**), apigenin (**23**) [61]. From ethanolic extract of *B. anisandra*, was found the

flavonoid quercetin-3-O-rhamnoside (**24**) [29]. Quercetin is found in a wide variety of plants and studies showed that can reduce infectivity of target cells and replication against a wide variety of respiratory viruses, like HSV-1 and HSV-2, adenovirus (AdV-3, AdV-8 and AdV-11) and coronavirus [62-64], parainfluenza virus type 3, respiratory syncytial virus [65] and rhinovirus [66].

TANNINS

Tannins are defined as water-soluble phenol compounds that are able to bind and precipitate proteins and other macromolecules within aqueous solutions [67]. They are found in all of plants and play important roles of defense against herbivory by generalists [68] and pathogenic microorganisms [69]. They have very high variability in their structures with several hundred unique molecules detected in plants [70]. However, the overall tannin composition of many plant species is yet unknown.

The Malpighiaceae family, as well as the *Banisteriopsis* species, presented high concentration of condensed tannins [71, 72]. These consist of two or




Figure 3: Tannins founded in *Banisteriopsis* species.

more monomeric (+) – catechin (**25**) or (-) – epicatechin (**26**) units [67]. From metanolic extract of *B. variabilis*, were isolated the epicatechin and epicatechin gallate or epigallocatechin (**27**) (Queiroz *et al.* 2011) and procyanidin was found in *B. caapi* extract B2 (**28**) [61].

Oki (2005), studying four species of *Banisteriopsis* (*B. stellaris*, *B. pubipetala*, *B. adenopoda*, *B. argyrophylla*) during two years in Cerrado areas verified that the tannin concentration varied according to species, development phase and seasons of year. Among the species studied, the lowest concentration was found in *B. adenopoda* leaves (5.3% dw) while *B. stellaris* presented the highest concentration (16.9% dw) during dry season. The study also showed that the old leaves had higher tannin concentration than new leaves during dry season. For *Banisteriopsis* species, the exposure time of the leaves and water stress can favor the production of tannin in dry season [71].

On the other hand, during rainy season the old leaves presented lower concentration of tannin than new leaves in almost all species studied. In this rainy period there is a high diversity of herbivores and it is probable that the high content of tannin found in new *Banisteriopsis* species leaves is related to herbivore pressure [71]. New leaves are considered as an ephemeral resource and it is frequent the investment in chemical defense mainly in period of high herbivory pressure.

TERPENOIDS

Aquino *et al.* (1991) reported terpenoids from *B. caapi* [72]. In leaves of *B. anisandra*, there were reported the steroids stigmasterol (**28**), β -sitosterol (**29**), β -sitosterol oleate (**30**), the pentacyclic triterpene ursolic acid (**31**), oleanolic acid (**32**), fridelin (**33**), glochidonol (**34**), lupenone (**35**) and the sesquiterpene




Figure 4: Terpenoids founded in *Banisteriopsis* species.




Figure 5: Example of Miscellaneous metabolites found in *Banisteriopsis* species.

nerolidol (**36**) [29]. Recently, Pinho *et al.* (2009) reported that the seeds of *B. pubipetala* and *B. harleyi* contains high concentrations of oil (43.5% and 46.5% respectively), largely unsaturated, with high content of linoleic acid, high oleic and linolenic fatty acid (*B. pubipetala*) and mono-unsaturated gadoleic acid (*B. harleyi*) [73].

The administration of oleanolic acid demonstrated decrease CCl₄ induced liver parenchymal cell necrosis, steatosis, and prevents CCl₄ plus alcohol-induced chronic cirrhosis in rats [74, 75]. Oleanolic acid protects against the hepatotoxicity produced also by acetaminophen, cadmium, bromobenzene, phalloidin, thioacetamide, furosemide, colchicine [76]. However ursolic acid also protects against D-galactosamine-induced liver injury in rats, and prevents acetaminophen-induced cholestasis [77]. The anti-inflammatory effect of oleanolic acid was described by Gupta *et al.* (1969). They reported the inhibitory effects of oleanolic acid on carrageenan-induced rat paw edema and formaldehyde-induced arthritis [78]. The mechanisms of anti-inflammatory effects have been attributed to the following aspects: (1) Inhibition of histamine; (2) inhibition of lipoxygenase and cyclooxygenase activity reducing some inflammatory factors produced during arachidonic acid cascade; (3) inhibition of elastase [79].

MISCELLANEOUS METABOLITES

The disaccharide β -D-fructofuranosyl-(2 \rightarrow 5)-fructopyranose (**38**) were also isolated by Samoylenko (2010) [34]. The metabolites 2-hydroxy-6-methoxy-7-

metil-9,10-dihydrophenanthrene-1-carbaldehyde (**39**), 2,8-hydroxy-6-methoxy-7-methyl-9,10-dihydrophenanthrene-1-carbaldehyde (**40**), 2-hydroxy-6,8-methoxy-7-methyl-9,10-dihydrophenanthrene-1-carbaldehyde (**41**); oleic acid (**42**) and protocatechuic acid (**43**) were reported in extracts of *B. anisandra* [29].

CONCLUSION

Banisteriopsis species are both metabolically and taxonomically diverse and showing enormous metabolic capabilities and production of diverse bioactivity structures. The metabolites found in *Banisteriopsis* can be used to drug prototypes to many pathological or physiological situations.

ACKNOWLEDGEMENTS

This work was supported by the Minas Gerais Stat Research Foundation (FAPEMIG) and by the National Council for Scientific and Technological Development (CNPq).

REFERENCES

- [1] Mabberley DJ. The plant book: A portable dictionary of the vascular plants. 2nd ed. Cambridge: Cambridge University Press 1997.
- [2] Schultes RE. The Botanical and chemical distribution of hallucinogens. *J Psychedelic Drugs* 1977; 9: 247-63. <http://dx.doi.org/10.1080/02791072.1977.10472055>
- [3] Callaway JC, McKenna DJ, Grob CS, *et al.* Pharmacokinetics of Hoasca alkaloids in healthy humans. *J Ethnopharmacol.* 1999; 65: 243-56. [http://dx.doi.org/10.1016/S0378-8741\(98\)00168-8](http://dx.doi.org/10.1016/S0378-8741(98)00168-8)
- [4] Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and

- cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. *J Pharmacol Exp Ther* 2003; 306: 73-83. <http://dx.doi.org/10.1124/jpet.103.049882>
- [5] Callaway J. Various alkaloid profiles in decoctions of *Banisteriopsis caapi*. *J Psychoactive Drugs* 2005; 37: 151-5. <http://dx.doi.org/10.1080/02791072.2005.10399796>
- [6] Pomilio A, Vitale A, Ciprian-Ollivier J, Cetkovich-Bakmas M, Gomez R, Vazquez G. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. *J Ethnopharmacol* 1999; 65: 29-51. [http://dx.doi.org/10.1016/S0378-8741\(98\)00163-9](http://dx.doi.org/10.1016/S0378-8741(98)00163-9)
- [7] Rodd R. Reassessing the cultural and psychopharmacological significance of *Banisteriopsis caapi*: preparation, classification and use among the Piaroa of southern Venezuela. *J Psychoactive Drugs* 2008; 40: 301-7. [http://dx.doi.org/10.1016/S0378-8741\(98\)00163-9](http://dx.doi.org/10.1016/S0378-8741(98)00163-9)
- [8] Santos R, Landeira-Fernandez J, Strassman R, Motta V, Cruz A. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. *J Ethnopharmacol* 2007; 112: 507-13. <http://dx.doi.org/10.1016/j.jep.2007.04.012>
- [9] McKenna D. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. *Pharmacol Ther* 2004; 102: 111-29. <http://dx.doi.org/10.1016/j.pharmthera.2004.03.002>
- [10] Brierley DI, Davidson C. Developments in harmine pharmacology - Implications for ayahuasca use and drug-dependence treatment. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012; in press. <http://dx.doi.org/10.1016/j.pnpbp.2012.06.001>
- [11] McKenna D, Towers G, Abbott F. Monoamine-oxidase inhibitors in South-American hallucinogenic plants - tryptamine and beta-carboline constituents of Ayahuasca. *J Ethnopharmacol* 1984; 10: 195-223. [http://dx.doi.org/10.1016/0378-8741\(84\)90003-5](http://dx.doi.org/10.1016/0378-8741(84)90003-5)
- [12] Monsef H, Ghobadi A, Iranshahi M, Abdollahi M. Antinociceptive effects of *Peganum harmala* L. alkaloid extract on mouse formalin test. *J Pharm Pharm Sci*. 2004; 7: 65-9. <http://dx.doi.org/10.1016/j.jep.2010.07.048>
- [13] Farouk L, Laroubi A, Aboufatima R, Benharref A, Chait A. Evaluation of the analgesic effect of alkaloid extract of *Peganum harmala* L.: Possible mechanisms involved. *J Ethnopharmacol* 2008; 115: 449-54. <http://dx.doi.org/10.1016/j.jep.2007.10.014>
- [14] Lamchouri F, Settaf A, Cherrah Y, et al. *In vitro* cell-toxicity of *Peganum harmala* alkaloids on cancerous cell-lines. *Fitoterapia* 2000; 71: 50-4. [http://dx.doi.org/10.1016/S0367-326X\(99\)00117-3](http://dx.doi.org/10.1016/S0367-326X(99)00117-3)
- [15] Sobhani AM ES, Hoormand M, Rahbar N, Mahmoudian M. Cytotoxicity of *Peganum harmala* L. seeds extract and its relationship with contents of beta-carboline alkaloids. *J Iran Univ Med Sci* 2002; 8: 432-8.
- [16] Jahaniani F, Ebrahimi S, Rahbar-Roshandel N, Mahmoudian M. Xanthomicrol is the main cytotoxic component of *Dracocephalum kotschyii* and a potential anti-cancer agent. *Phytochemistry* 2005; 66: 1581-92. <http://dx.doi.org/10.1016/j.phytochem.2005.04.035>
- [17] Ayoub MT, Al-Allaf TAK, Rashan LJ. Antiproliferative activity of harmol, a beta-carboline alkaloid. *Fitoterapia* 1994; 65: 14-8.
- [18] Shi CC, Liao JF, Chen CF. Comparative study on the vasorelaxant effects of three harmala alkaloids *in vitro*. *Jpn J Pharmacol*. 2001; 85: 299-305. <http://dx.doi.org/10.1254/jjp.85.299>
- [19] Berrougui H, Martín-Cordero C, Khalil A, et al. Vasorelaxant effects of harmine and harmaline extracted from *Peganum harmala* L. seeds in isolated rat aorta. *Pharmacol Res* 2006; 54: 150-7. <http://dx.doi.org/10.1016/j.phrs.2006.04.001>
- [20] Astulla A, Zaima K, Matsuno Y, et al. Alkaloids from the seeds of *Peganum harmala* showing antiparasitoid and vasorelaxant activities. *J Nat Med* 2008; 62: 470-2. <http://dx.doi.org/10.1007/s11418-008-0259-7>
- [21] Abdel-Fattah AF, Matsumoto K, Gammaz HA, Watanabe H. Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism. *Pharmacol Biochem Behav* 1995; 52: 421-6. [http://dx.doi.org/10.1016/0091-3057\(95\)00131-F](http://dx.doi.org/10.1016/0091-3057(95)00131-F)
- [22] Kuhn MA, Winston D. *Herbal Therapy & Supplements: A scientific & traditional approach*. 2nd ed: New York: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2000.
- [23] Prashanth D, John S. Antibacterial activity of *Peganum harmala*. *Fitoterapia* 1999; 70: 438-9. [http://dx.doi.org/10.1016/S0367-326X\(99\)00065-9](http://dx.doi.org/10.1016/S0367-326X(99)00065-9)
- [24] Arshad N, Neubauer C, Hasnain S, Hess M. *Peganum harmala* can minimize *Escherichia coli* infection in poultry, but long-term feeding may induce side effects. *Poult Sci* 2008; 87: 240-9. <http://dx.doi.org/10.3382/ps.2007-00341>
- [25] Kim H, Sablin SO, Ramsay RR. Inhibition of monoamine oxidase a by beta-carboline derivatives. *Arch Biochem Biophys* 1997; 337: 137-42. <http://dx.doi.org/10.1006/abbi.1996.9771>
- [26] Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD. Activities of extract and constituents of *Banisteriopsis caapi* relevant to parkinsonism. *Pharmacol Biochem Behav* 2003; 75: 627-33. [http://dx.doi.org/10.1016/S0091-3057\(03\)00129-1](http://dx.doi.org/10.1016/S0091-3057(03)00129-1)
- [27] Zheng XY, Zhang ZJ, Chou GX, et al. Acetylcholinesterase inhibitive activity-guided isolation of two new alkaloids from seeds of *Peganum nigellastrum* Bunge by an *in vitro* TLC-bioautographic assay. *Arch Pharm Res* 2009; 32: 1245-51. <http://dx.doi.org/10.1007/s12272-009-1910-x>
- [28] Bussmann RW, Malca-García G, Glenn A, et al. Minimum inhibitory concentrations of medicinal plants used in Northern Peru as antibacterial remedies. *J Ethnopharmacol* 2010; 132: 101-8. <http://dx.doi.org/10.1016/j.jep.2010.07.048>
- [29] Freitas LBO. Estudo Fitoquímico e da Atividade Biológica de *Banisteriopsis anisandra* (A.Juss) B. Gates e Síntese de Amidas Indólicas para Avaliação da Atividade Alelopática. [dissertation]. Belo Horizonte (MG): Universidade Federal de Minas Gerais 2010; p. 236.
- [30] Frias UA, Mendes Costa MC, Aparecida Takahashi J. Caracterización fitoquímica y de las actividades antibacterianas y anticolinesterasa de *Banisteriopsis anisandra* A. Juss. (Malpigiaceae). *Rev Cubana Plant Med* 2011; 16: 11.
- [31] Hashimoto Y, Kawanishi K. New organic bases from Amazonian *Banisteriopsis caapi*. *Phytochemistry* 1975; 14: 1633-5. [http://dx.doi.org/10.1016/0031-9422\(75\)85365-9](http://dx.doi.org/10.1016/0031-9422(75)85365-9)
- [32] Hashimoto Y, Kawanishi K. New alkaloids from *Banisteriopsis caapi*. *Phytochemistry* 1976; 15: 1559-60. [http://dx.doi.org/10.1016/S0031-9422\(00\)88936-0](http://dx.doi.org/10.1016/S0031-9422(00)88936-0)
- [33] Kawanishi K, Uhara Y, Hashimoto Y. Shihunine and dihydroshihunine from *Banisteriopsis caapi*. *J Nat Prod* 1982; 45: 637-9. <http://dx.doi.org/10.1021/np50023a021>
- [34] Samoylenko V, Rahman MM, Tekwani BL, et al. *Banisteriopsis caapi*, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease. *J Ethnopharmacol* 2010; 127: 357-67. <http://dx.doi.org/10.1016/j.jep.2009.10.030>
- [35] Ghosal S, Mazumder UK. Alkaloids of the leaves of *Banisteriopsis argentea*. *Phytochemistry* 1971; 10: 2840-2. [http://dx.doi.org/10.1016/S0031-9422\(00\)97304-7](http://dx.doi.org/10.1016/S0031-9422(00)97304-7)

- [36] Aricioglu F, Altunbas H. Harmine induces anxiolysis and antidepressant-like effects in rats. *Ann N Y Acad Sci* 2003; 1009: 196-201.
<http://dx.doi.org/10.1196/annals.1304.024>
- [37] Nenaah G. Antibacterial and antifungal activities of (beta)-carboline alkaloids of *Peganum harmala* (L) seeds and their combination effects. *Fitoterapia* 2010; 81: 779-82.
<http://dx.doi.org/10.1016/j.fitote.2010.04.004>
- [38] Im J-H, Jin Y-R, Lee J-J, et al. Antiplatelet activity of beta-carboline alkaloids from *Peganum harmala*: A possible mechanism through inhibiting PLCgamma2 phosphorylation. *Vasc Pharmacol* 2009; 50: 147-52.
<http://dx.doi.org/10.1016/j.vph.2008.11.008>
- [39] Aarons DH, Rossi GV, Orzechowski RF. Cardiovascular actions of three harmala alkaloids: harmine, harmaline, and harmalol. *J Pharm Sci* 1977; 66: 1244-8.
<http://dx.doi.org/10.1002/jps.2600660910>
- [40] Rodriguez E, Cavin JC, West JE. The possible role of Amazonian psychoactive plants in the chemotherapy of parasitic worms - a hypothesis. *J Ethnopharmacol* 1982; 6: 303-9.
[http://dx.doi.org/10.1016/0378-8741\(82\)90053-8](http://dx.doi.org/10.1016/0378-8741(82)90053-8)
- [41] Hopp KH, Cunningham LV, Bromel MC, Schermeister LJ, Khalil SK. *In vitro* antitrypanosomal activity of certain alkaloids against *Trypanosoma lewisi*. *Lloydia* 1976; 39: 375-7.
- [42] Lala S, Pramanick S, Mukhopadhyay S, Bandyopadhyay S, Basu MK. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. *J Drug Target* 2004; 12: 165-75.
<http://dx.doi.org/10.1080/10611860410001712696>
- [43] Di Giorgio C, Delmas F, Ollivier E, Elias R, Balansard G, Timon-David P. *In vitro* activity of the beta-carboline alkaloids harmine, harmine, and harmaline toward parasites of the species *Leishmania infantum*. *Exp Parasitol* 2004; 106: 67-74.
<http://dx.doi.org/10.1016/j.exppara.2004.04.002>
- [44] Zhao T, He YQ, Wang J, Ding KM, Wang CH, Wang ZT. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by beta-carboline alkaloids, harmine derivatives. *Phytother Res* 2011; 25: 1671-7.
<http://dx.doi.org/10.1002/ptr.3458>
- [45] El Gendy MA, Soshilov AA, Denison MS, El-Kadi AO. Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanisms. *Food Chem Toxicol* 2012; 50: 353-62.
<http://dx.doi.org/10.1016/j.fct.2011.10.052>
- [46] El Gendy MA, Soshilov AA, Denison MS, El-Kadi AO. Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol. *Toxicol Lett* 2012; 208: 51-61.
<http://dx.doi.org/10.1016/j.fct.2011.10.052>
- [47] Kim DH, Jang YY, Han ES, Lee CS. Protective effect of harmaline and harmalol against dopamine- and 6-hydroxydopamine-induced oxidative damage of brain mitochondria and synaptosomes, and viability loss of PC12 cells. *Eur J Neurosci* 2001; 13: 1861-72.
<http://dx.doi.org/10.1046/j.0953-816x.2001.01563.x>
- [48] Knoll J. (-) Deprenyl (Selegiline): past, present and future. An authoritative review of the pharmacological aspects of l-deprenyl (Selegiline). *Neurobiology* 2000; 8: 179-99.
- [49] Miralles A, Esteban S, Sastre-Coll A, Moranta D, Asensio V, Garcia-Sevilla J. High-affinity binding of, beta-carbolines to imidazoline I-2B receptors and MAO-A in rat tissues: Norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain. *Eur J Pharmacol* 2005; 518: 234-42.
<http://dx.doi.org/10.1016/j.ejphar.2005.06.023>
- [50] Ruiz-Durántez E, Torrecilla M, Pineda J, Ugedo L. Attenuation of acute and chronic effects of morphine by the imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline in rat locus coeruleus neurons. *Br J Pharmacol* 2003; 138: 494-500.
<http://dx.doi.org/10.1038/sj.bjp.0705052>
- [51] Pereira M, Grubbs C, Barnes L, et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. *Carcinogenesis* 1996; 17: 1305-11.
<http://dx.doi.org/10.1093/carcin/17.6.1305>
- [52] Caltagirone S, Ranelletti FO, Rinelli A, et al. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. *Am J Respir Cell Mol Biol* 1997; 17: 51-9.
- [53] Aviram M, Furhman B. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. *Atherosclerosis* 1998; 137(Suppl 1): S45-S50.
- [54] Siess M, Leclerc J, Canivenclavier M, Rat P, Suschetet M. Heterogenous effects of natural flavonoids on monoxygenase activities in human and rat-liver microsomes. *Toxicol Appl Pharmacol* 1995; 130: 73-8.
<http://dx.doi.org/10.1006/taap.1995.1010>
- [55] Agullo G, Gamet-Payrastré L, Manenti S, et al. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. *Biochem Pharmacol* 1997; 53: 1649-57.
[http://dx.doi.org/10.1016/S0006-2952\(97\)82453-7](http://dx.doi.org/10.1016/S0006-2952(97)82453-7)
- [56] Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. *Proc Natl Acad Sci USA* 1998; 95: 9831-6.
<http://dx.doi.org/10.1073/pnas.95.17.9831>
- [57] Geleijnse JM, Launer LJ, Hofman A, Pols HA, Witteman JC. Tea flavonoids may protect against atherosclerosis: the Rotterdam Study. *Arch Intern Med* 1999; 159: 2170-4.
<http://dx.doi.org/10.1001/archinte.159.18.2170>
- [58] Sesso HD, Gaziano JM, Buring JE, Hennekens CH. Coffee and tea intake and the risk of myocardial infarction. *Am J Epidemiol* 1999; 149: 162-7.
<http://dx.doi.org/10.1093/oxfordjournals.aje.a009782>
- [59] Frias UA, Siligardi HMT, Mendes-Costa MC. Caracterização fitoquímica e determinação da atividade anticolinesterásica de *Banisteriopsis* sp. Proceedings of the Semana da Química 2011, May 23-26; Lavras (MG), Brazil.
- [60] Simoni IC, S. MP, Sciessere L, Hoe VMH, Takinami VH, Fernandes MJB. Evaluation of the antiviral activity of Brazilian cerrado. *Virus Res* 2009; 12: 1-17.
- [61] Queiroz, MMF, Pilon AC, Neto FC, et al. Detecção de constituintes micromoleculares majoritários presentes nas folhas de *Banisteriopsis variabilis* (Malpighiaceae) utilizando UHPLC-ESI-IT-EM. Proceedings of the 34th Reunião Anual da Sociedade Brasileira de Química 2011, May 23-26; Florianópolis (SC), Brazil.
- [62] Noltemper S, Reichling J, Sensch KH, Schnitzler P. Mechanism of herpes simplex virus type 2 suppression by propolis extracts. *Phytomedicine* 2010; 17: 132-8.
<http://dx.doi.org/10.1016/j.phymed.2009.07.006>
- [63] Debiaggi M, Tateo F, Pagani L, Luini M, Romero E. Effects of propolis flavonoids on virus infectivity and replication. *Microbiologica* 1990; 13: 207-13.
- [64] Chiang LC, Chiang W, Liu MC, Lin CC. *In vitro* antiviral activities of *Caesalpinia pulcherrima* and its related flavonoids. *J Antimicrob Chemother* 2003; 52: 194-8.
<http://dx.doi.org/10.1093/jac/dkg291>

- [65] Kaul TN, Middleton E, Ogra PL. Antiviral effect of flavonoids on human viruses. *J Med Virol* 1985; 15: 71-9.
- [66] Dimova S, Mugabowindekwe R, Willems T, *et al.* Safety-assessment of 3-methoxyquercetin as an antirhinoviral compound for nasal application: effect on ciliary beat frequency. *Int J Pharm* 2003; 263: 8. [http://dx.doi.org/10.1016/S0378-5173\(03\)00363-6](http://dx.doi.org/10.1016/S0378-5173(03)00363-6)
- [67] Salminen J-P, Karonen M. Chemical ecology of tannins and other phenolics: we need a change in approach. *Funct Ecol* 2011; 25: 325-38. <http://dx.doi.org/10.1111/j.1365-2435.2010.01826.x>
- [68] Feeny P. Plant apparency and chemical defense. In: Wallace JW, Mansell RL (Eds.) *Recent Advances in Phytochemistry*. 10 v. New York: Plenum 1976; p. 1-40.
- [69] Bernays EA, Chapman RF. Chemicals in plants. In: Bernays EA, Chapman, RF (Eds). *Host-plant selection by phytophagous insects*. New York: Chapman & Hall 1994; p. 14-60.
- [70] Cronquist A. *An Integrated System of Classification of Flowering Plants*. New York: Columbia University Press 1981; p. 1262.
- [71] Oki Y. Interações entre larvas de Lepidoptera e as espécies de Malpighiaceae em dois fragmentos de Cerrado do Estado de São Paulo. [thesis]. Ribeirão Preto (SP): Universidade de São Paulo 2005; p. 145.
- [72] Aquino R, De Crescenzo S, De Simone F. Constituents of *Banisteriopsis caapi*. *Fitoterapia* 1991; 62: 453.
- [73] Pinho R, Oliveira A, Silva S. Potential oilseed crops from the semiarid region of northeastern Brazil. *Bioresour Technol* 2009; 100: 6114-7. <http://dx.doi.org/10.1016/j.biortech.2009.06.010>
- [74] Ma X-H, Yuan-Chang Z, Lei Y, De-Wu H, Chun-Xuan J. Studies on the effect of oleanolic acid on experimental liver injury. *Yao Xue Xue Bao* 1982; 17: 93-7.
- [75] Han DW, Ma XH, Zhao YC, Yin L. The protective effects of oleanolic acid on experimental cirrhosis. *J Tradit Chin Med* 1981; 3: 217-23.
- [76] Liu J, Liu YP, Klaassen CD. Protective effect of oleanolic acid against chemical-induced acute necrotic liver injury in mice. *Zhongguo Yao Li Xue Bao* 1995; 16: 97-102.
- [77] Shukla B, Visen PKS, Patnaik GK, *et al.* Hepatoprotective activity in the rat of ursolic acid isolated from eucalyptus hybrid. *Phytother Res* 1992; 6: 74-9. [http://dx.doi.org/10.1002/\(SICI\)1099-1573\(200005\)14:3<163::AID-PTR588>3.0.CO;2-D](http://dx.doi.org/10.1002/(SICI)1099-1573(200005)14:3<163::AID-PTR588>3.0.CO;2-D)
- [78] Gupta M, Bhalla T, Gupta G, Mitra C, Bhargava K. Anti-inflammatory activity of natural products - I. Triterpenoids. *Eur J Pharmacol* 1969; 6: 67-70.
- [79] Liu H. Oleanolic acid and ursolic acid: Research perspectives. *J Ethnopharmacol* 2005; 100: 92-4. <http://dx.doi.org/10.1016/j.jep.2005.05.024>

Received on 01-05-2012

Accepted on 05-09-2012

Published on 19-09-2012

DOI: <http://dx.doi.org/10.6000/1927-3037/2012.01.03.02>© 2012 Frias *et al.*; Licensee Lifescience Global.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.